Related Experiment Video
Updated: May 13, 2026
08:45
Assessing Cellular Target Engagement by SHP2 (PTPN11) Phosphatase Inhibitors
Published on: July 17, 2020
Targeting SIRPα in cancer
Jenny M Ho1, Jayne S Danska, Jean C Y Wang
1The Campbell Family Cancer Research Institute; Ontario Cancer Institute; Princess Margaret Hospital; Toronto, ON Canada.
Oncoimmunology
|March 26, 2013
Summary
Harnessing the immune system for cancer therapy can involve enhancing macrophage-mediated leukemia cell clearance. Blocking inhibitory signals from signal regulatory protein alpha (SIRPα) offers an alternative immunotherapy approach.
Area of Science:
- Immunology
- Oncology
- Cancer immunotherapy
Background:
- Adoptive T-cell transfer is a primary strategy for cancer immunotherapy.
- Alternative approaches are needed to enhance the immune system's cancer-fighting capabilities.
Purpose of the Study:
- To explore an alternative immunotherapy strategy for cancer.
- To investigate enhancing macrophage-mediated clearance of leukemia cells.
Main Methods:
- Blocking inhibitory signals transmitted by signal regulatory protein alpha (SIRPα).
Main Results:
- The study highlights an alternative immunotherapeutic approach.
- Enhancing macrophage-mediated clearance of leukemia cells is a key finding.
Conclusions:
- Blocking SIRPα is a promising strategy for cancer immunotherapy.
- This approach offers a novel way to combat leukemia.
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:23Abnormal Proliferation
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
03:03mTOR Signaling and Cancer Progression
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...